Brought to you by 
Actavis shells out $23 per share for Durata; deal valued at $616mm
01 Jun 2021
Executive Summary
In a move that significantly enhances its emerging infectious disease business, specialty pharmaco Actavis PLC is acquiring public Irish firm Durata Therapeutics Inc. for $23.00 in cash per share (a 75% premium), valuing the transaction at $616mm. Actavis will also issue Durata stockholders contingent value rights (CVRs) to receive up to $5.00 per share if certain regulatory and commercial milestones are met for its lead product Dalvance (dalbavancin).
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Acquisition
- Full Acquisition
- Includes Earnout
- Payment Includes Cash for Equity
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Actavis shells out $23 per share for Durata; deal valued at $616mm
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice